Evidence map›Paper›PMID 38766189›Full record

ArticlebioRxiv : the preprint server for biology2025

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.

Yaniv Kazansky, Helen S Mueller, Daniel Cameron, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Prabhjot S Mundi, Yasumichi Kuwahara, Romel Somwar and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Yaniv KazanskyMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3467-5703
Helen S MuellerMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel CameronMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Phillip DemarestMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nadia ZaffaroniMolecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Noemi ArrighettiMolecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Valentina ZucoMolecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Prabhjot S MundiDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-9871-4463
Yasumichi KuwaharaDepartment of Biochemistry and Molecular Biology, Kyoto Prefectural University of Medicine.
Romel SomwarDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rui QuAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea CalifanoDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-4742-3679
Elisa de StanchinaAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8356-5191
Andrew L KungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mrinal M GounderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alex KentsisMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8063-9191

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5M
Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5M
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell levelU01CA272610 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2022 to 2026
$4.8M
Structure and function of genome plasticity in human cancerR01CA214812 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2018 to 2022
$2.5M
High Performance Computing Cluster for Biomedical ResearchS10OD032433 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2023 to 2023
$2.0M
High-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0M
Storage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694NCI NIH HHS R01 CA214812NCI NIH HHS R35 CA197745NCI NIH HHS U01 CA272610NIGMS NIH HHS T32 GM007739NIH HHS S10 OD012351NIH HHS S10 OD021764NIH HHS S10 OD032433
6 · The paper itself

Abstract

Despite the potential of targeted epigenetic therapies, most cancers do not respond to current epigenetic drugs. The Polycomb repressive complex EZH2 inhibitor tazemetostat was recently approved for the treatment of

Indexed as

BAFcombination therapyepigeneticsEZH2 inhibitionPRC2

Identifiers

PMID38766189
PMCPMC11100591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.